Cochrane Review Group

Heart

140 systematic reviews in Heart ask 1,554 questions. 17.5% have no studies to answer them, 21.2% rest on very low certainty evidence and 28.6% reach moderate or high certainty.

Reviews

140

Questions

1,554

current versions

No studies

17.5%

Moderate or high

28.6%

No studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Heart

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Exercise‐based cardiac rehabilitation vs usual care HRQoL (all measurement scales) · adults with heart failure Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane	no estimate extracted	33 studies · 4769 participants	Very low
Prophylactic corticosteroids vs placebo or no corticosteroids Length of hospital stay (measured in days, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with… Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane	no estimate extracted	25 studies · 1841 participants	Very low
Mobile phone text messaging vs usual care Medication adherence (self‐reported adherence, questionnaire, tablet counts, medication event monitoring systems, pharmacy prescription data) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	18 studies · 8136 participants	Very low
Mobile phone text messaging vs usual care Non‐fatal cardiovascular events (percentage of people having non‐fatal cardiovascular events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	Very low
Mobile phone text messaging vs usual care Combined CVD events (percentage of people having combined CVD events) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	Very low
Mobile phone text messaging vs usual care Low‐density lipoprotein cholesterol (mg/dL) (endpoint low‐density lipoprotein cholesterol reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	8 studies · 4983 participants	Very low
Mobile phone text messaging vs usual care Blood pressure (mmHg) (endpoint blood pressure reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	8 studies · 5173 participants	Very low
Mobile phone text messaging vs usual care Heart rate (beats per minute) (endpoint heart rate reading) · people with established arterial occlusive events Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	4 studies · 2946 participants	Very low
Mindfulness‐based interventions (MBIs) vs active comparators Clinical CVD events · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	No studies
Mindfulness‐based interventions (MBIs) vs non‐active comparators Clinical CVD events (CVD mortality and non‐fatal MI) · people at high risk of or withcardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	RR 0.94 [0.37, 2.42]	1 study · 110 participants	Very low
Transcendental meditation (TM) vs active comparators Perceived stress, change from baseline · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	3 studies · 194 participants	Very low
Transcendental meditation (TM) vs active comparators Well‐being · people at high risk of or with cardiovascular disease Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 140

Mobile phone‐based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults

Palmer, MJ, Machiyama, K, et al. · Cochrane Database of Systematic Reviews · 2021

Heart

Thinnest evidence

Reviews 140

Mobile phone‐based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction

Stem cell therapy for dilated cardiomyopathy

Intermittent fasting for the prevention of cardiovascular disease

Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases

Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias

Ultrasound guidance for arterial (other than femoral) catheterisation in adults

Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis

Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease

Trypanocidal drugs for late‐stage, symptomatic Chagas disease (Trypanosoma cruzi infection)

Intravenous immunoglobulin for presumed viral myocarditis in children and adults

Interventions for increasing fruit and vegetable consumption in children aged five years and under

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome

A comparison of different antibiotic regimens for the treatment of infective endocarditis

Reduction in saturated fat intake for cardiovascular disease

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

mHealth education interventions in heart failure

Mechanical assist devices for acute cardiogenic shock

Ivabradine as adjuvant treatment for chronic heart failure

Advance care planning for adults with heart failure

Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass

Physical activity interventions for people with congenital heart disease

Effects of total fat intake on body fatness in adults

Disease management interventions for heart failure

Adrenaline and vasopressin for cardiac arrest